Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma
Background: Proton beam has an excellent depth dose distribution due to its unique physical properties, and thus proton beam therapy (PBT) has been tried and showed promising outcomes in hepatocellular carcinoma (HCC). The purpose of this phase II study is to evaluate the efficacy of hypofractionate...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00542/full |
| _version_ | 1831774121477799936 |
|---|---|
| author | Tae Hyun Kim Tae Hyun Kim Joong-Won Park Bo Hyun Kim Eun Sang Oh Sang Hee Youn Sung Ho Moon Sang Soo Kim Sang Myung Woo Young-Hwan Koh Woo Jin Lee Dae Yong Kim |
| author_facet | Tae Hyun Kim Tae Hyun Kim Joong-Won Park Bo Hyun Kim Eun Sang Oh Sang Hee Youn Sung Ho Moon Sang Soo Kim Sang Myung Woo Young-Hwan Koh Woo Jin Lee Dae Yong Kim |
| author_sort | Tae Hyun Kim |
| collection | DOAJ |
| description | Background: Proton beam has an excellent depth dose distribution due to its unique physical properties, and thus proton beam therapy (PBT) has been tried and showed promising outcomes in hepatocellular carcinoma (HCC). The purpose of this phase II study is to evaluate the efficacy of hypofractionated PBT in HCC.Methods: The eligibility criteria for this study were as follows: patients with HCC lesion(s) who were failed after, were difficult to treat with, or refused to other local treatments; tumor size and number of ≤7 and ≤2 cm, respectively, and HCC lesion(s) of ≥2 cm from gastrointestinal organs; Child–Pugh score of ≤7; Eastern Cooperative Oncology Group performance status ≤1; and age ≥18 years. The prescribed dose of PBT was 70 Gy equivalent in 10 fractions. The primary endpoint was 3-year local progression-free survival (LPFS) rate.Results: Forty-five patients were prospectively enrolled, and there were 35 men and 10 women with a median age of 63 years (range, 46–78 years). Thirty-seven patients had recurrent and/or residual disease, and eight patients had treatment-naive disease. All patients received the planned treatments without treatment interruption, and grade ≥3 acute toxicity did not occur. The median follow-up duration was 35.1 months (range, 11.2–56.3 months) and local progression occurred in two patients (8.7%). The 3-year rates of LPFS and overall survival (OS) were 95.2% (95% confidence interval [CI], 89.1%−100%) and 86.4% (95% CI, 72.9–99.9%), respectively.Conclusion: Hypofractionated PBT showed promising LPFS and OS, and further studies are warranted to compare PBT with other local modalities. |
| first_indexed | 2024-12-22T08:48:40Z |
| format | Article |
| id | doaj.art-d3666da340874112b1eeb879f34b93a4 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T08:48:40Z |
| publishDate | 2020-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d3666da340874112b1eeb879f34b93a42022-12-21T18:32:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-04-011010.3389/fonc.2020.00542532515Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular CarcinomaTae Hyun Kim0Tae Hyun Kim1Joong-Won Park2Bo Hyun Kim3Eun Sang Oh4Sang Hee Youn5Sung Ho Moon6Sang Soo Kim7Sang Myung Woo8Young-Hwan Koh9Woo Jin Lee10Dae Yong Kim11Center for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Proton Therapy, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Proton Therapy, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Proton Therapy, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Proton Therapy, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Proton Therapy, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaCenter for Proton Therapy, Research Institute and Hospital, National Cancer Center, Goyang, South KoreaBackground: Proton beam has an excellent depth dose distribution due to its unique physical properties, and thus proton beam therapy (PBT) has been tried and showed promising outcomes in hepatocellular carcinoma (HCC). The purpose of this phase II study is to evaluate the efficacy of hypofractionated PBT in HCC.Methods: The eligibility criteria for this study were as follows: patients with HCC lesion(s) who were failed after, were difficult to treat with, or refused to other local treatments; tumor size and number of ≤7 and ≤2 cm, respectively, and HCC lesion(s) of ≥2 cm from gastrointestinal organs; Child–Pugh score of ≤7; Eastern Cooperative Oncology Group performance status ≤1; and age ≥18 years. The prescribed dose of PBT was 70 Gy equivalent in 10 fractions. The primary endpoint was 3-year local progression-free survival (LPFS) rate.Results: Forty-five patients were prospectively enrolled, and there were 35 men and 10 women with a median age of 63 years (range, 46–78 years). Thirty-seven patients had recurrent and/or residual disease, and eight patients had treatment-naive disease. All patients received the planned treatments without treatment interruption, and grade ≥3 acute toxicity did not occur. The median follow-up duration was 35.1 months (range, 11.2–56.3 months) and local progression occurred in two patients (8.7%). The 3-year rates of LPFS and overall survival (OS) were 95.2% (95% confidence interval [CI], 89.1%−100%) and 86.4% (95% CI, 72.9–99.9%), respectively.Conclusion: Hypofractionated PBT showed promising LPFS and OS, and further studies are warranted to compare PBT with other local modalities.https://www.frontiersin.org/article/10.3389/fonc.2020.00542/fullhepatocellular carcinomaoverall survivallocal progression-free survivalproton beam therapyradiotherapy |
| spellingShingle | Tae Hyun Kim Tae Hyun Kim Joong-Won Park Bo Hyun Kim Eun Sang Oh Sang Hee Youn Sung Ho Moon Sang Soo Kim Sang Myung Woo Young-Hwan Koh Woo Jin Lee Dae Yong Kim Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma Frontiers in Oncology hepatocellular carcinoma overall survival local progression-free survival proton beam therapy radiotherapy |
| title | Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma |
| title_full | Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma |
| title_fullStr | Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma |
| title_full_unstemmed | Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma |
| title_short | Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma |
| title_sort | phase ii study of hypofractionated proton beam therapy for hepatocellular carcinoma |
| topic | hepatocellular carcinoma overall survival local progression-free survival proton beam therapy radiotherapy |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.00542/full |
| work_keys_str_mv | AT taehyunkim phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT taehyunkim phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT joongwonpark phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT bohyunkim phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT eunsangoh phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT sangheeyoun phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT sunghomoon phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT sangsookim phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT sangmyungwoo phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT younghwankoh phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT woojinlee phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma AT daeyongkim phaseiistudyofhypofractionatedprotonbeamtherapyforhepatocellularcarcinoma |